Contribution: Industrial Research Assistance Program – Contributions to Firms
Entos Pharmaceuticals Inc.
$75,000.00
MNC Collab - FOCUS2024 - Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye
FY 2024-25 · 2024-11-01
Summary
As part of Multinational Corporate Collaboration Program, the project “Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye” will focus on the evaluation of the safety and effectiveness of a gene, encoded in partner mRNA, in correcting an ophthalmological disease when delivered to the eye using Firm's proprietary drug delivery technology platform. The project will have two phases: (1) Formulation of proteolipid vehicle (PLV) with partner mRNA cargo followed by (2) in vitro assessment of efficacy and tolerability.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Edmonton|Edmonton, Alberta, Canada
Recipient Type
For-profit organization
Business Number
816561112
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2025-03-31
Agreement Number
1024027
Agreement Start Date
2024-11-01
Agreement Title
MNC Collab - FOCUS2024 - Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye
Agreement Title (French)
MNC Collab — FOCUS2024 — Développement de la formulation de Fusogenix pour l’administration sûre et puissante d’acides nucléiques dans l’œil
Agreement Type
Contribution
Agreement Value
$75,000.00
Amendment Number
0
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
As part of Multinational Corporate Collaboration Program, the project “Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye” will focus on the evaluation of the safety and effectiveness of a gene, encoded in partner mRNA, in correcting an ophthalmological disease when delivered to the eye using Firm's proprietary drug delivery technology platform. The project will have two phases: (1) Formulation of proteolipid vehicle (PLV) with partner mRNA cargo followed by (2) in vitro assessment of efficacy and tolerability.
Description (French)
Dans le cadre du programme de collaboration entre entreprises multinationales, le projet « Fusogenix Formulation Development for Safe and Potent Delivery of Nucleic Acid Cargoes in the Eye » se concentrera sur l’évaluation de la sécurité et de l’efficacité d’un gène, codé dans l’ARNm d’un partenaire, dans la correction d’une maladie ophtalmologique lorsqu’il est administré dans l’œil à l’aide de la plateforme technologique d’administration de médicaments brevetée de l’entreprise. Le projet comprendra deux phases : (1) la formulation d’un véhicule protéolipidique (PLV) avec l’ARNm partenaire suivi par (2) l’évaluation in vitro de l’efficacité et de la tolérabilité.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Centre
Federal Riding (French)
Edmonton-Centre
Federal Riding Number
48014
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
816561112
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
Entos Pharmaceuticals Inc.
Recipient Postal Code
T5J 4P6
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2024-2025-Q3-1024027
